HER2 Biomarkers
Guardant Health, Boehringer Ingelheim Partner on Companion Diagnostic for New Lung Cancer Drug
The companies aim to establish Guardant360 CDx as a tool to identify patients with HER2 mutations eligible for treatment with the targeted drug zongertinib.
HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
Reveal Genomics Studying HER2DX Test Impact on Breast Cancer Treatment Decisions
The trial done in collaboration with the Istituto Europeo di Oncologia will assess how the test influences oncologists' treatment plans for early-stage breast cancer patients.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
Concr Exploring Biomarkers of Response to Neoadjuvant TNBC Therapy
The firm will use its AI-based platform to create "digital twins" of TNBC patients and predict neoadjuvant treatment response.